• Growth and margin guidance: Molbio expects 25% annual revenue growth and around 25% EBITDA margins for the full year, noting that public health procurement causes non-linear performance with only 35% to 45% of business occurring in the first half.
• IPO proceeds utilization: Out of the ₹200 crore raised in primary capital, the company has allocated approximately ₹107 crore toward a new R&D facility and over ₹70 crore for automation to drive manufacturing efficiency.
• Export mix expansion: Operating across 80 low- and middle-income countries, the company is expanding into developed markets like the US and Europe, aiming to raise export revenue contribution from 15% to 25%–30% (and up to 40%) over the next 3 to 4 years.
• Diagnostic pipeline development: Beyond its primary TB testing vertical, Molbio is expanding its Truenat platform to cover Hepatitis B and C, HPV, and STIs, while developing 20 to 22 new tests for rollout within 1 to 2 years.